Born of two years of meticulous research and a significant investment of US$50,000 from its seed round funding, MelaMe is a revolutionary proprietary technology and formula designed specifically to solve hyperpigmentation in Indian skin tones. This first-of-its-kind innovation has undergone rigorous clinical trials, with product testing conducted on men and women aged between 18 and 35 years possessing dull and dry skin with dark spots and visible pores. Clinically proving its effectiveness this complex is a testament to Asaya’s unwavering dedication to melanated skin. 

MelaMe is engineered to effectively address prevalent skin concerns among melanated skin, like dark spots, pigment imbalance, and discoloration. These issues often worsen from external stressors like harsh UV rays and pollution, making effective treatment necessary. MelaMe's active properties inhibit excess melanin production while dispersing and dissolving existing melanin deposits, offering a comprehensive solution. Unlike traditional depigmenting agents designed with lighter skin tones in mind, MelaMe™ does not cause skin irritation or compromise the skin barrier. Instead, it employs a unique mechanism called Melanophagy, where excess melanin is disassembled into amino acids and reabsorbed—providing faster and safer results.

“With the launch of MelaMe, we are not just introducing a product; we are bringing a solution crafted with the Indian consumer in mind,” said Eeti Sharma, Co-Founder of Asaya. “India’s first-of-its-kind formulation addresses a concern that most skincare brands have long overlooked. We are proud to engineer a revolutionary molecule that truly understands Indian skin types, offering our skin a melanin-first solution to depigmentation.”